• Our Science

    Programs developing molecules to amplify immune recognition of cancers

  • Clinical Trials

    Targeting various cancers either in monotherapy or in combination

  • Working at iTeos

    Recruiting top talent for both our US and Belgium sites

Pipeline

iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.

The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.

Learn more about our pipeline
Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Key upcoming milestones
EOS-850
Monotherapy Solid tumors
Initial expansion results 1H 2021
+ pembrolizumab PD-1-Resistant Melanoma
Initiation 3Q 2020
+ pembrolizumab Castrate-R Prostate Cancer
Initiation 3Q 2020
+ Pac-Carbo TNBC
Initiation 3Q 2020
EOS-448
Dose Finding, PK/PD Solid tumors
Presentation of initial results 1H 2021
Mono / + Combo Multiple Myeloma
Initiation mid-2021
+ PD-(L)1 NSCLC
Initiation mid-2021
+ EOS-850 +/- Chemo Solid Tumors
Initiation mid-2021
Adenosine Pathway Inhibitor
Oncology
Candidate selection 1Q 2021

Our latest news

  • iTeos Therapeutics Announces Pricing of Initial Public Offering

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

    – EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020 – – EOS-448 has shown potent antitumor activity and a favourable tolerability profile in preclinical studies –   Cambridge, MA and

  • iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

    Cambridge, MA and Gosselies, Belgium – June 15, 2020.  iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today that it will present

  • iTeos Therapeutics Strengthens Leadership Team

    – Matthew Gall joins as Chief Financial Officer   – Dr Yvonne McGrath joins as Vice President of R&D  – Philippe Brantegem joins as Vice President of Human Resources  Cambridge, MA and Gosselies, Belgium – June 9, 2020  –   iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company

  • iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors

    Cambridge, MA and Gosselies, Belgium – June 1, 2020  –   iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointment of Ann D.

  • iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    – Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed – – EOS-850 showed preliminary single-agent clinical benefit in seven patients who continue to present

  • iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    Gosselies, Belgium and Cambridge, MA – April 20, 2020.  iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A 2A  receptor

  • iTeos Therapeutics Closes $125 Million Series B2 Financing

     - Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A 2A  adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW

  • iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

    – First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials – – Initial clinical data expected in 1H 2021 –